Linezolid: Effectiveness and safety for approved and off-label indications

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2381-2400

  Vardakas, Konstantinos Z ^a   Ntziora, Fotinie ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Bacteremia; Endocarditis; Gram positive infection; Linezolid; Methicillin resistant S. aureus; Pneumonia; Skin and soft tissue infection; Vancomycin; Vancomycin resistant Enterococcus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFADROXIL; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DEXTROMETHORPHAN; DICLOXACILLIN; GENTAMICIN; LINEZOLID; MACROLIDE; OXACILLIN; PENICILLIN DERIVATIVE; PHENYLPROPANOLAMINE; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOEPHEDRINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

AGE; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; AUTOIMMUNE THROMBOCYTOPENIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BLURRED VISION; BONE INFECTION; BONE MARROW SUPPRESSION; CELLULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONVULSION; COST CONTROL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS; ERADICATION THERAPY; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HOSPITALIZATION COST; HUMAN; HYPERTENSION; IMMUNOCOMPROMISED PATIENT; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OBESITY; OFF LABEL DRUG USE; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REVIEW; SEROTONIN SYNDROME; SEX DIFFERENCE; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; OXAZOLIDINONES;

EID: 35548935306     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2381     Document Type: Review

References (128)

1. FLUCKIGER U, WIDMER AF: Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy (1999) 45(2):121-134.
2. JONES RN, LOW DE, PFALLER MA: Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. (1999) 33(2):101-112.
3. RICHARDS MJ, EDWARDS JR, CULVER DH, GAYNES RP: Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. (2000) 21(8):510-515.
4. VINCENT JL, BIHARI DJ, SUTER PM et al.: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC international advisory committee. JAMA (1995) 274(8):639-644.
5. DOERN GV, JONES RN, PFALLER MA, KUGLER KC, BEACH ML: Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). SENTRY study group (North America). Diagn. Microbiol. Infect. Dis. (1999) 34(1):65-72.
6. RENNIE RP, JONES RN, MUTNICK AH; SENTRY PROGRAM STUDY GROUP (NORTH AMERICA): Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY antimicrobial surveillance program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. (2003) 45(4):287-293.
7. SMITH TL, PEARSON ML, WILCOX KR et al.: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group. N. Engl. J. Med. (1999) 340(7):493-501.
8. LOW DE, KELLER N, BARTH A, JONES RN: Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of Enterococci: results from the SENTRY antimicrobial surveillance program, 1997 - 1999. Clin. Infect. Dis. (2001) 32(Suppl. 2):S133-S145.
9. ABRAMSON MA, SEXTON DJ: Nosocomial methicillin- resistant and methicillin-susceptible Staphylococcus aureus primary bacteraemia: at what costs? Infect. Control Hosp. Epidemiol. (1999) 20(6):408-411.
10. BATTS DH: Linezolid - a new option for treating gram-positive infections. Oncology (Williston Park). (2000) 14(8 Suppl. 6):23-29.
11. FRENCH G: Linezolid. Int. J. Clin. Pract. (2001) 55(1):59-63.
12. AMENT PW, JAMSHED N, HORNE JP: Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am. Fam. Physician (2002) 65(4):663-670.
13. ABB J: In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method. Diagn. Microbiol. Infect. Dis. (2002) 43(4):319-321.
14. BALLOW CH, JONES RN, BIENDENBACH DJ: A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. (2002) 43(1):75-83.
15. TILL M, WIXSON RL, PERTEL PE: Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. (2002) 34(10):1412-1414.
16. YANIGAHARA K, KANEKO Y, SAWAI T et al.: Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection. Antimicrob. Agents Chemother. (2002) 46(10):3288-3291.
17. CLEMETT D, MARKHAM A: Linezolid. Drugs (2000) 59(4):815-827.
18. RYBAK MJ, CAPPELLETTY DM, MOLDOVAN T, AESCHLIMANN JR, KAATZ GW: Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents. Chemother. (1998) 42(3):721-724.
19. BOWKER KE, WOOTTON M, HOLT HA, MACGOWAN AP: In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. J. Antimicrob. Chemother. (2002) 49(3):578-580.
20. FORD CW, HAMEL JC, WILSON DM et al.: In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob. Agents Chemother. (1996) 40(6):1508-1513.
21. ORAMAS-SHIREY MP, BUCHAHAN LV, DILETO-FANG CL et al.: Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J. Antimicrob. Chemother. (2001) 47(3):349-352.
22. ZURENKO GE, YAGI BH, SCHAADT RD et al.: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. (1996) 40(4):839-845.
23. WISE R: Clinical efficacy and antimicrobial pharmacodynamics. Hosp. Med. (2000) 61(1):24-30.
24. PANKEY GA, SABATH LD: Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. (2004) 38(6):864-870.
25. PALADINO JA: Linezolid: an oxazolidinone antimicrobial agent. Am. J. Health Syst. Pharm. (2002) 59(24):2413-2425.
26. BRICKNER SJ, HUTCHINSON DK, BARBACHYN MR et al.: Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. (1996) 39(3):673-679.
27. SHINABARGER DL, MAROTTI KR, MURRAY RW et al.: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. (1997) 41(10):2132-2136.
28. SHINABARGER D: Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs (1999) 8(8):1195-1202.
29. ZURENKO GE, GIBSON JK, SHINABARGER DL, ARISTOFF PA, FORD CW, TARPLEY WG: Oxazolidinones: a new class of antibacterials. Curr. Opin. Pharmacol. (2001) 1(5):470-476.
30. DRESSER LD, RYBAK MJ: The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy (1998) 18(3):456-462.
31. NOSKIN GA, SIDDIQUI F, STOSOR V, HACEK D, PETERSON LR: In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant Enterococci. Antimicrob. Agents Chemother. (1999) 43(8):2059-2062.
32. LIN AH, MURRAY RW, VIDMAR TJ, MAROTTI KR: The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. (1997) 41(10):2127-2131.
33. MUTNICK AH, ENNEV, JONES RN: Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann. Pharmacother. (2003) 37(6):769-774.
34. SEEDAT J, ZICK G, KLARE I, KONSTABEL C, WEILER N, SAHLY H: Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob. Agents Chemother. (2006) 50(12):4217-4219.
35. KLOSS P, XIONG L, SHINABARGER DL, MANKIN AS: Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J. Mol. Biol. (1999) 294(1):93-101.
36. PRYSTOWSKY J, SIDDIQUI F, CHOSAY J et al.: Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant Enterococci. Antimicrob. Agents Chemother. (2001) 45(7):2154-2156.
37. JONES RN, DELLA-LATTA P, LEE LV, BIENDENBACH DJ: Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. (2002) 42(2):137-139.
38. AUCKLAND C, TEARE C, COOKE F et al.: Linezolid-resistant Enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. (2002) 50(5):743-746.
39. JOHNSON AP, TYSALL L, STOCKDALE MV et al.: Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. (2002) 21(10):751-754.
40. TSIODRAS S, GOLD HS, SAKOULAS G et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358(9277):207-208.
41. XIONG L, KLOSS P, DOUTHWAITE S et al.: Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J. Bacteriol. (2000) 182(19):5325-5331.
42. BOZDOGAN B, APPELBAUM PC: Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents (2004) 23(2):113-119.
43. WOLTER N, SMITH AM, FARELL DJ et al.: Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. (2005) 49(8):3554-3557.
44. PRUNIER AL, MALBRUNY B, LAURANS M, BROUARD J, DUHAMEL JF, LECLERCQ R: High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. (2003) 187(11):1709-1716.
45. CORTI G, CINELLI R, PARADISI F: Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Int. J. Antimicrob. Agents (2000) 16(4):527-530.
46. LIN AH, MURRAY RW, VIDMAR TJ, MAROTTI KR: The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. (1997) 41(10):2127-2131.
47. SWANEY SM, AOKI H, GANOZA MC, SHINABARGER DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. (1998) 42(12):3251-3255.
48. HANCOCK RE: Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect. Dis. (2005) 5(4):209-218.
49. CRAIG WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. (2003) 17(3):479-501.
50. DIMITRIU G, POIATA A, TUCHILUS C, BUIUC D: Correlation between linezolid zone diameter and minimum inhibitory concentration values determined by regression analysis. Rev. Med. Chir. Soc. Med. Nat. Iasi (2006) 110(4):1016-1019.
51. ANDES D, VAN OGTROP ML, PENG J, CRAIG WA: In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. (2002) 46(11):3484-3489.
52. GEE T, ELLIS R, MARSHALL G, ANDREWS J, ASHBY J, WISE R: Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. (2001) 45(6):1843-1846.
53. HYATT JM, MCKINNON PS, ZIMMER GS, SCHENTAG JJ: The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. (1995) 28(2):143-160.
54. WISE R, ANDREWS JM, BOSWELL FJ, ASHBY JP: The in vitro activity of linezolid (U-100766) and tentative breakpoints. J. Antimicrob. Chemother. (1998) 42(6):721-728.
55. DIEKEMA DI, JONES RN: Oxazolidinones: a review. Drugs (2000) 59(1):7-16.
56. FRENCH G: Safety and tolerability of linezolid. J. Antimicrob. Chemother. (2003) 51(Suppl. 2):II45-II53.
57. LI Z, WILLKE RJ, PINTO LA et al.: Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy. (2001) 21(3):263-274.
58. STALKER DJ, JUNGBLUTH GL: Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. (2003) 42(13):1129-1140.
59. STALKER DJ, JUNGBLUTH GL, HOPKINS NK, BATTS DH: Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J. Antimicrob. Chemother. (2003) 51(5):1239-1246.
60. SLATTER JG, STALKER DJ, FEENSTRA KL et al.: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab. Dispos. (2001) 29(8):1136-1145.
61. MACGOWAN AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. (2003) 51(Suppl 2):II17-II25.
62. STEVENS DL, DOTTER B, MADARAS-KELLY K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev. Anti. Infect. Ther. (2004) 2(1):51-59.
63. CONTE JE Jr, GOLDEN JA, KIPPS J, ZURLINDEN E: Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. (2002) 46(5):1475-1480.
64. SABBATANI S, MANFREDI R, FRANK G, CHIODO F: Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds. Infez. Med. (2005) 13(2):112-119.
65. BUERGER C, PLOCK N, DEHGHANYAR P, JOUKHADAR C, KLOFT C: Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother. (2006) 50(7):2455-2463.
66. LOVERING AM, ZHANG J, BANNISTER GC et al.: Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. (2002) 50(1):73-77.
67. RANA B, BUTCHER I, GRIGORIS P, MURNAGHAN C, SEATON RA, TOBIN CM: Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother. (2002) 50(5):747-750.
68. KEARNS GL, ABDEL-RAHMAN SM, BLUMER JL et al.: Single dose pharmacokinetics of linezolid in infants and children. Pediatr. Infect. Dis. J. (2000) 19(12):1178-1184.
69. JUNGBLUTH GL, WELSHMAN IR, HOPKINS NK: Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr. Infect. Dis. J. (2003) 22(9 Suppl.):S153-S157.
70. KAPLAN SL: Use of linezolid in children. Pediatr. Infect. Dis. J. (2002) 21(9):870-872.
71. VELISSARIOU IM: Use of linezolid in children: an overview of recent advances. Expert Rev. Anti. Infect. Ther. (2006) 4(6):947-952.
72. STEIN GE, SCHOOLEY SL, PELOQUIN CA et al.: Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann. Pharmacother. (2005) 39(3):427-432.
73. SISSON TL, JUNGBLUTH GL, HOPKINS NK: Age and sex effects on the pharmacokinetics of linezolid. Eur. J. Clin. Pharmacol. (2002) 57(11):793-797.
74. HENDERSHOT PE, ANTAL EJ, WELSHMAN IR, BATTS DH, HOPKINS NK: Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J. Clin. Pharmacol. (2001) 41(5):563-572.
75. ANTAL EJ, HENDERSHOT PE, BATTS DH, SHEU WP, HOPKINS NK, DONALDSON KM: Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J. Clin. Pharmacol. (2001) 41(5):552-562.
76. TAYLOR JJ, ESTES LL, WILSON JW: Linezolid and serotonergic drug interactions. Clin. Infect. Dis. (2006) 43(10):1371.
77. CAMMARATA SK, BERMUDEZ M, GOLIN V et al.: Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized community-acquired pneumonia. Program and Abstracts of the 9th International Congress on Infectious Diseases. Buenos Aires, Argentina (Boston: International Society of Infectious Diseases, 2000). (2000) (Abstr. 80.008).
78. CAMMARATA SK, SCHUEMAN LK, TIMM JA et al.: Oral linezolid in the treatment of community-acquired pneumonia: a Phase III trial. Program and Abstracts of the American Thoracic Society. Toronto, Canada. (New York: American Thoracic Society, 2000:654). (2000) (Abstr. E73).
79. SAN PEDRO GS, CAMMARATA SK, OLIPHANT TH, TODISCO T; LINEZOLID COMMUNITY-ACQUIRED PNEUMONIA STUDY GROUP: Linezolid versus ceftriaxone/ cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand. J. Infect. Dis. (2002) 34(10):720-728.
80. CEPEDA JA, WHITEHOUSE T, COOPER B: Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J. Antimicrob. Chemother. (2004) 53(2):345-355.
81. WILCOX M, NATHWANI D, DRYDEN M: Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J. Antimicrob. Chemother. (2004) 53(2):335-344.
82. WUNDERINK RG, CAMMARATA SK, OLIPHANT TH, KOLLEF MH; LINEZOLID NOSOCOMIAL PNEUMONIA STUDY GROUP: Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. (2003) 25(3):980-992.
83. KAPLAN SL, DEVILLE JG, YOGEV R et al.: Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J. (2003) 22(8):677-686.
84. RUBINSTEIN E, CAMMARATA S, OLIPHANT T, WUNDERINK R; LINEZOLID NOSOCOMIAL PNEUMONIA STUDY GROUP: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. (2001) 32(3):402-412.
85. STEVENS DL, HERR D, LAMPIRIS H, HUNT JL, BATTS DH, HAFKIN B: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. (2002) 34(11):1481-1490.
86. CAMMARATA SK, WUNDERINK RG, HEMPSALL KA, TODD WM, HAFKIN B: Efficacy of linezolid in patients with nosocomial pneumonia based on severity of illness as determined by baseline APACHE II score. Abstracts of the 40th Interscience Conference on antimicrobial Agents and Chemotherapy. Toronto, Canada (American Society for Microbiology, Washington, DC, USA.) (2000):487 (Abstr. 2234).
87. WUNDERINK RG, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, KOLLEF MH: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124:1789-1797.
88. KOLLEF MH, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, WUNDERINK RG: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. (2004) 30:388-394.
89. IOANAS M, LODE H: Linezolid in VAP by MRSA: a better choice? Intensive Care Med. (2004) 30:343-346.
90. CRUCIANI M, GATTI G, LAZZARINI L et al.: Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother. (1996) 38(5):865-869.
91. HONEYBOURNE D, TOBIN C, JEVONS G, ANDREWS A, WISE R: Intrapulmonary penetration of linezolid. Chest (2002) 122(4 Supp1.):S159. (Abstract).
92. MICEK ST, DUNNE M, KOLLEF MH: Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest (2005) 128(4):2732-2738.
93. POWERS JH, ROSS DB, LIN D, SORETH J: Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest (2004) 126(1):314-315.
94. KALIL AC, PUUMALA SE, STONER J: Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest (2004) 125(6):2370-2371.
95. FALAGAS ME, SIEMPOS II, VARDAKAS KZ: Linezolid versus a glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: a meta-analysis of randomized controlled trials. Lancet Infect. Dis. (2007) (In Print).
96. JAKSIC B, MARTINELLI G, PEREZ-OTEYZA J, HARTMAN CS, LEONARD LB, TACK KJ: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin. Infect. Dis. (2006) 42:597-607.
97. JAUKEGUI LE, BABAZADEH S, SELTZER E et al.: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2005) 41:1407-1415.
98. SHARPE JN, SHIVELY EH, POLK HC Jr: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. (2005) 189(4):425-428.
99. WEIGELT J, ITANI K, STEVENS D, LAU W, DRYDEN M, KNIRSCH C: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. (2005) 49(6):2260-2266.
100. LIPSKY BA, ITANI K, NORDEN C: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. (2004) 38(1):17-24.
101. WIBLE K, TREGNAGHI M, BRUSS J, FLEISHAKER D, NABERHUIS-STEHOUWER S, HILTY M: Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr. Infect. Dis. J. (2003) 22(4):315-323.
102. DUVALL SE, SEAS C, BRUSS JB, MCCONNELL-MARTIN MA, TODD WM, HAFKIN B: Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: results from a multinational Phase III trial. Program and Abstracts of the 9th International Congress on Infectious Diseases. Buenos Aires, Argentina (Boston: International Society of Infectious Diseases, 2000:181) (2000). (Abstr. 80.005).
103. STEVENS DL, SMITH LG, BRUSS JB et al.: Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. (2000) 44(12):3408-3413.
104. BIRMINGHAM MC, RAYNER CR, MEAGHER AK, FLAVIN SM, BATTS DH, SCHENTAG JJ: Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. (2003) 36:159-168.
105. RAAD I, HACHEM R, HANNA H et al.: Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J. Antimicrob. Chemother. (2004) 53(4):646-649.
106. HARTMAN CS, LEACH TS, KAJA RW et al.: Linezolid in the treatment of vancomycin-resistant Enterococcus: a dose comparative, multicenter Phase III trial. 40th Interscience Coherence on Antimicrobial Agents and Chemotherapy. Toronto, Canada (Washington, DC: American Society for Microbiology, 2000:488.) (2000) (Abstr. 2235).
107. SHORR AF, KUNKEL MJ, KOLLEF M: Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. (2005) 56(5):923-929.
108. GÓMEZ J, GARCÍA-VÁ.ZQUEZ E, BAÑOS R et al.: Valdés predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur. J. Clin. Microbiol. Infect. Dis. (2007) 26:239-245.
109. VARDAKAS KZ, SAMONIS G, CHRYSANTHOPOULOU SA, BLIZIOTIS IA, FALAGAS ME: Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. (2005) 5:431-439.
110. BADDOUR LM, WILSON WR, BAYER AS et al.: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, american heart association: endorsed by the infectious diseases society of America. Circulation (2005) 111:E394-E434.
111. FALAGAS ME, MANTA KG, NTZIORA F, VARDAKAS KZ: Linezolid for the treatment of patients with endocarditis: a review of the published evidence. J. Antimicrob. Chemother. (2006) 58:273-280.
112. SENNEVILLE E, LEGOUT L, VALETTE M et al.: Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin. Ther. (2006) 28(8):1155-1163.
113. HARWOOD PJ, TALBOT C, DIMOUTSOS M et al.: Early experience with linezolid for infections in orthopaedics. Injury (2006) 37(9):818-826.
114. FALAGAS ME, SIEMPOS II, PAPAGELOPOULOS PJ, VARDAKAS KZ: Linezolid for the treatment of adults with bone and joint infections. Int. J. Antimicrob. Agents (2007) 29(3):233-239.
115. NTZIORA F, FALAGAS ME: Linezolid for the treatment of patients with CNS infection. Ann. Pharmacother. (2007) 41:296-308.
116. CYNAMON MH, KLEMENS SP, SHARPE CA, CHASE S: Activities of several novel oxalidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. (1999) 43:1189-1195.
117. NTZIORA F, FALAGAS ME: Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review. Int. J. Tuberc. Lung Dis. (2007) 11(6):606-611.
118. RUBINSTEIN E, ISTURIZ R, STANDIFORD HC et al.: Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob. Agents Chemother. (2003) 47(6):1824-1831.
119. NASRAWAY SA, SHORR AF, KUTER DJ, O'GRADY N, LE VH, CAMMARATA SK: Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin. Infect. Dis. (2003) 37(12):1609-1616.
120. VON DRYGALSKI A, CURTIS BR, BOUGIE DW et al.: Vancomycin-induced immune thrombocytopenia. N. Engl. J. Med. (2007) 356(9):904-910.
121. CORALLO CE, PAULL AE: Linezolid-induced neuropathy. Med. J. Aust. (2002) 177:332.
122. LEE E, BURGER S, SHAH J et al.: Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin. Infect. Dis. (2003) 37:1389-1391.
123. KOPTERIDES P, PAPADOMICHELAKIS E, ARMAGANIDIS A: Linezolid use associated with lactic acidosis. Scand. J. Infect. Dis. (2005) 37(2):153-154.
124. NATHWANI D: Impact of methicillin resistance Staphylococcus aureus on key health economic outcomes: does the length of hospital stay matter? J. Antimicrob. Chemother. (2003) 51(Suppl. 2):II37-II44.
125. FALAGAS ME, FRAGOULIS KN, KARYDIS I: A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS One (2006) 20:1:E11.
126. ITANI KMF, WEIGELT J, LI JZ, DUTTAGUPTA S: Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant S. aureus (MRSA). Int. J. Antimicrob. Agents (2005) 26:442-448.
127. NATHWANI D, LI JZ, BALAN DA: An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int. J. Antimicrob. Agents (2004) 23(4):315-324.
128. PLOSKER GL, FIGGITT DP: Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections. Pharmacoeconomics (2005) 23(9):945-964.